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Abstract
Background: Surviving expression might serve as a prognostic biomarker predicting the clinical outcome of non-
small cell lung cancer (NSCLC). The study was conducted to explore the potential correlation of survivin protein
expression with NSCLC and its clinicopathologic characteristics.
Methods: PubMed, Medline, Cochrane Library, CNKI and Wanfang database were searched through January 2016
with a set of inclusion and exclusion criteria. Data was extracted from these articles and all statistical analysis was
conducted by using Stata 12.0.
Results: A total of 28 literatures (14 studies in Chinese and 14 studies in English) were enrolled in this meta-analysis,
including 3206 NSCLC patients and 816 normal controls. The result of meta-analysis demonstrated a significant
difference of survivin positive expression between NSCLC patients and normal controls (RR = 7.16, 95 % CI = 4.63-11.07,
P < 0.001). To investigate the relationship of survivin expression and clinicopathologic characteristics, we performed a
meta-analysis in NSCLC patients. Our results indicates survivin expression was associated with histological
differentiation, tumor-node-metastasis (TNM) stage and lymph node metastasis (LNM) (RR = 0.80, 95 % CI = 0.73-0.87,
P < 0.001; RR = 0.75, 95 % CI = 0.67-0.84, P < 0.001; RR = 1.14, 95 % CI = 1.01-1.29, P = 0.035, respectively), but not
pathological type and tumor size. (RR = 1.00, 95 % CI = 0.93-1.07, P = 0.983; RR = 0.95, 95 % CI = 0.86-1.05, P = 0.336,
respectively).
Conclusion: Higher expression of survivin in NSCLC patients was found when compared to normal controls. Survivin
expression was associated with the clinicopathologic characteristics of NSCLC and may serves as an important
biomarker for NSCLC progression.
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Background
Non-small cell lung cancer (NSCLC) remains one of the
most fatal health problems in terms of morbidity and
mortality and is the leading cause of cancer-related mor-
talities worldwide [1]. Histologically, NSCLC is consisted
of three different subtypes: squamous cell carcinoma,
adenocarcinoma, and large cell carcinoma, accounting
for approximately 80 % ~ 85 % of lung cancer [2]. NSCLC
is highly resistant to the existing cancer therapeutics and
the great majority of NSCLC patients are diagnosed at
advanced tumor stage. Although the recent advances in
clinical and experimental oncology the survival of ad-
vanced NSCLC are still poor, with a 5-year survival rate of
about 15 % [3, 4].
It is generally accepted that abnormal inhibition of
apoptosis during homeostasis plays an important role in
cancer development, progression and resistance to ther-
apy [5]. Survivin, the common member of the inhibitor
of the apoptosis protein (IAP) family, is a protein
encoded by the BIRC5 gene in human with dual role in
promoting cell proliferation and preventing apoptosis
[6]. Previous studies revealed that survivin expression
was found in precancerous lesions as well as in early
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stages of cancer in the skin, uterine cervix, colon, and
oral mucosa [7, 8]. It was reported that survivin expres-
sion might serve as a prognostic biomarker predicting
the clinical outcome of NSCLC, and might be associated
with the clinicopathologic characteristics of NSCLC [5].
Perobska I et al. showed that lymph node metastases,
tumor node metastasis (TNM) stage and tumor size had
a higher incidence of survivin expression [9]. In order to
clarify the relation between survivin expression and
NSCLC, we conducted this meta-analysis.
Methods
Publication search
Online electronic databases (PubMed, Medline,
Cochrane Library, CNKI and Wanfang) were searched
with the key terms: (survivin or survivin protein) and
(non-small cell lung cancer or NSCLC or non-small-cell
lung carcinoma) (update to January 2016). We also
checked out the reference lists of all retrieved studies and
relevant reviews manually for important cross-references.
Inclusion and exclusion criteria
Published studies were selected if they met all of the fol-
lowing criteria: (1) The study must be conducted in
NSCLC patients; (2) The study must evaluate the Survivin
protein expression; (3) Sufficient data, especially survivin
positive expression in NSCLC patients and normal con-
trols, have been provided to calculate risk ratios (RR) and
95 % confidence interval (95 % CI); (4) Number of NSCLC
cases in enrolled studies should be more than 60; (5) The
study must be published in a peer-reviewed journal; (6)
The study must be independent from other studies. The
exclusion criteria were as follows: (1) The studies did not
conform to the inclusion criteria; (2) Reviews, case re-
ports, editorials, guidelines and comments were excluded;
(3) In case of duplicated publications or studies with over-
lapping data, the study with largest data was selected.
Data extraction and qualitative assessment
The following data were collected from all the included
studies: first author, publication year, country, ethnicity
of participants, language, and numbers of participants,
age, gender, subcellular localization and positive expres-
sion of survivin. Data from the finally selected studies
were extracted based on a standard protocol. Potential
discrepancy was resolved by discussions or by consulting
the original report. Two reviewers independently assessed
the methodological quality of the included trials using
the Newcastle-Ottawa Scale (NOS) criteria to ensure
consistency in reviewing and reporting results. The
studies were scored based on three aspects: (1) selection
of study group; (2) comparability of study groups; (3) as-
certainment of the outcome of interest. A study was
considered as low, moderate or high quality with the score
0 ~ 3, 4 ~ 6 and 7 ~ 9, respectively. Disagreement was
settled by discussion, or a third investigator was consulted.
Statistical analysis
Statistical test was conducted with the STATA statistical
software (Version 12.0, Stata Corporation, College Station,
TX, USA). To assess the correlation between survivin pro-
tein expression and the clinicopathologic characteristics,
RR and its 95 % CI were calculated using random effects
model or fixed-effects model. The statistical significance
of pooled RRs was estimated by the application of Z test.
We used Cochran’s Q-statistic (P < 0.05 was considered
significant) and I2 test to assess heterogeneity among stud-
ies. Random effects model was applied for the evidence of
significant heterogeneity (P < 0.05 or I2 test exhibited >
50 %); otherwise, fixed-effects model was used. Univariate
and multivariate meta-regression analyses were used to
evaluate the potential sources of heterogeneity. Further
identification was performed by using Monte Carlo
method. Additionally, we applied a sensitivity analysis to
evaluate whether one single study had the weight to
impact on the overall estimate. Further, the effect of
publication bias was examined by Egger’s linear regres-
sion test (P < 0.05 was considered significant).
Results
Literature searching results and baseline characteristics of
included studies
Four hundred and eighty-seven articles were initially identi-
fied through database searches. Twenty-eight studies
remained after excluding duplicates (n = 42), letters, re-
views, meta-analyses (n = 46) and irrelevant topic (n = 273),
non-core journal in Chinese (n = 36), insufficient informa-
tion in studies (n = 35) and number of NSCLC cases less
than 60 (n = 27), 28 trials were finally selected for this
meta-analysis (Fig. 1) [5, 10–36]. The enrolled studies pub-
lished between 2005 and 2015 included 3206 NSCLC pa-
tients and 816 normal controls, with 2252 males and 954
females. For the pathological type, 1010 patients with squa-
mous cell carcinoma (SCC), 806 with adenocarcinoma
(AC). With respect to clinicopathologic features, 1198 pa-
tients with well/moderate differentiation, 788 with poor dif-
ferentiation; 1421 at I/II stage and 1009 at III/IV stage
(TNM stage); 1256 patients with lymphatic metastasis and
1185 patients without lymphatic metastasis. All included
studies scored 7 in terms of NOS scores. The baseline char-
acteristics of included studies were showed in Table 1.
The comparison between NSCLC patients and normal
controls on survivin protein expression
A total of 19 studies provided data of survivin expression in
NSCLC patients and normal controls (1537 NSCLC pa-
tients and 816 normal controls). Heterogeneity test revealed
the existence of heterogeneity in those 19 trials, thus a
Duan et al. BMC Cancer  (2016) 16:276 Page 2 of 10
random-effect model was used (I2 = 58.1 %, P < 0.001).
Meta-analysis result revealed that survivin expression
in NSCLC patients was significantly higher when com-
pared with normal controls (RR = 7.16, 95 % CI = 4.63-
11.07, P < 0.001) (Fig. 2).
The analysis of survivin expression and clinicopathologic
characteristics of NSCLC
For the meta-analysis according to pathological types,
we included 22 studies, involving 1010 SCC patients and
806 AC patients. Heterogeneity test revealed the lack of
heterogeneity in these studies and a fixed-effect model
was applied (I2 = 7 %, P = 0.367). No significantly different
survivin expression was found between squamous cell car-
cinoma (SCC) and adenocarcinoma (AC) (RR = 1.00, 95 %
CI = 0.93-1.07, P = 0.983) (Fig. 3). A total of 21 studies
investigated histological differentiation of NSCLC pa-
tients and moderate heterogeneity existed in these
studies (I2 = 45.4 %, P = 0.013). Results from random-
effect model suggested that survivin expression was sig-
nificantly lower in NSCLC patients with well/moderate
differentiation than that in the patients with poor dif-
ferentiation (RR = 0.80, 95 % CI = 0.73-0.87, P < 0.001)
(Fig. 4). 26 studies provided survivin expression level at
different TNM stages. Heterogeneity test showed the
presence of heterogeneity in these studies (I2 = 72.7 %,
P < 0.001). Meta-analysis results revealed that NSCLC
patients at TNM III/IV stage had a significantly higher
survivin expression than the patients at TNM I/II stage
(RR = 0.75, 95 % CI = 0.67-0.84, P < 0.001) (Fig. 5). A
total of 25 studies indicated the status of lymphatic metas-
tasis. Meta-analysis suggested that survivin expression in
NSCLC patients with lymphatic metastasis was signifi-
cantly higher than that in the patients without lymphatic
metastasis (RR = 1.14, 95 % CI = 1.01-1.29, P = 0.035)
(Fig. 6). 11 studies showed the survivin expression in the
patient with different tumor size. No heterogeneity was
found in these studies (I2 = 18.1 %, P = 0.272). Meta-
analysis revealed that survivin expression was not asso-
ciated with tumor size (RR = 0.95, 95 % CI = 0.86-1.05,
P = 0.336) (Fig. 7).
We also performed subgroup analysis according to the
ethnicity. And the results showed survivin expression
was associated with respect to histological differenti-
ation, TNM stage and lymph node metastasis in Asian
populations but not in Caucasian populations. (Table 2)
For Caucasians, only the contrast of NSCLC versus and

























Fig. 1 PRISMA Flow chart of study selection procedure
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to the definition of positive expression, the studies were
divided in to 3 subgroups. (1 Survivin expressed in
cytoplasm only, 2 Survivin expressed in cytoplasm or nu-
cleus, 3 Survivin expressed in both cytoplasm and nucleus)
Subgroup analysis found survivin expression was associ-
ated with histological differentiation, TNM stage and
lymph node metastasis in subgroup 1 and subgroup 2, but
not in subgroup 3. (Table 3)
Sensitivity analysis and publication bias
The sensitivity analysis demonstrated that a single study
had no significant effect on the pooled RRs. Egger’s test
based on the 19 literatures which provided the compari-
son between NSCLC patients and normal controls re-
vealed the presence of publication bias (P = 0.001). After
the application of fill and trim method, statistical signifi-
cance still existed on the survivin expression between
NSCLC patients and normal controls (P < 0.001), sug-
gesting publication bias has no significant effect on the
final results. For those studies investigated pathological
types (n = 22), histological differentiation (n = 21), TNM
stage (n = 26), lymphatic metastasis (n = 25) and tumor
size (n = 11), no publication biases were found by Egger’s
test.
Meta-regression analysis
Univariate meta-regression analysis revealed that coun-
try and ethnicity may be the potential sources for most
of heterogeneity (P > 0.05). Multivariate meta-regression
analysis further confirmed this finding (Table 4).
Discussion
The tumorigenesis of NSCLC is a complex process with
the feature of imbalance in cell apoptosis and proliferation.
Table 1 Baseline characteristics of included studies
First author Year Country Ethnicity Language Disease Method Case Number Sample source Gender (M/F) Age (years)
Hirano H 2015 Japan Asians English NSCLC IHC 157 tissue 115/42 66.7(47–82)
Hu S 2013 China Asians English NSCLC IHC 256 tissue 176/80 57.7
Sun PL 2013 Korea Asians English NSCLC IHC 373 tissue 258/115 65.0(21–84)
Zhang XY 2012 China Asians Chinese NSCLC IHC(SP) 60 tissue 35/25 54.0(30–78)
Peng X 2012 China Asians English NSCLC IHC 97 tissue 75/22 58.3(28–75)
Wang M 2012 China Asians English NSCLC IHC 210 tissue 130/80 59.8(35–76)
Gao Q 2012 China Asians English NSCLC IHC 62 tissue 44/18 57.8(35–78)
Hu FQ 2011 China Asians Chinese NSCLC IHC(Envision) 116 tissue 78/38 65.8(35–84)
Guosheng L 2011 China Asians English NSCLC IHC(SP) 100 tissue 69/31 55.6(37–76)
Fan CF 2011 China Asians English NSCLC IHC 76 tissue 46/30 57.1(26–78)
Zhu CZ 2010 China Asians Chinese NSCLC IHC(SP) 60 tissue 39/21 62.1(33–78)
Yang DX 2010 China Asians Chinese NSCLC IHC(PowerVision) 60 tissue 40/20 53.5(37–71)
Zeng ZH 2010 China Asians Chinese NSCLC IHC 60 tissue 38/22 65.7(40–78)
Porebska I 2010 Poland Caucasians English NSCLC IHC 74 tissue 49/25 60.5(43–77)
Chen YQ 2009 China Asians English NSCLC IHC(SP) 120 tissue 94/26 61.0(42–76)
Li CH 2008 China Asians Chinese NSCLC IHC(PV) 91 tissue 77/14 62.0(39–78)
Shi M 2007 China Asians Chinese NSCLC IHC 80 tissue 55/25 56.2(33–79)
Miao LJ 2007 China Asians Chinese NSCLC IHC(SP) 80 tissue 53/27 58.8(18–78)
Xue ZX 2006 China Asians Chinese NSCLC IHC(SP) 84 tissue 51/33 53.2(22–75)
Wang M 2006 China Asians Chinese NSCLC IHC 72 tissue 45/27 58.5(38–74)
Li XC 2006 China Asians Chinese NSCLC IHC(SABC) 64 tissue 41/23 55.6(35–78)
Yoo J 2006 Korea Asians English NSCLC IHC 219 tissue 168/51 65.8 ± 9.9
Huo XD 2006 China Asians Chinese NSCLC IHC(Envision) 117 tissue 85/32 57.5(29–71)
Vischioni B 2006 Netherlands Caucasians English NSCLC IHC 160 tissue 129/31 64.0(40–86)
Akyurek N 2006 Turkey Caucasians English NSCLC IHC 78 tissue 72/6 60.8(39–78)
Ren YJ 2006 China Asians Chinese NSCLC IHC(Envision) 61 tissue 45/16 62.0(40–75)
Qiu HL 2005 China Asians Chinese NSCLC IHC(SP) 75 tissue 51/24 57.1 ± 10.6
Shinohara ET 2005 America Caucasians English NSCLC IHC 144 tissue 94/50 65.4 ± 11.04
(Notes: NSCLC = non-small cell lung cancer; IHC = Immunohistochemical;M =male; F = female; OA = osteoarthritis)
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Fig. 2 Forest plots for the comparisons of survivin expression between NSCLC patients and normal controls
Fig. 3 Forest plots for the comparisons of survivin expression between SCC patients and AC patients
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Fig. 4 Forest plots for the comparisons of survivin expression between well/moderated differentiated patients and poor differentiated patient
Fig. 5 Forest plots for the comparisons of survivin expression between patients at TNM I/II stage and TNM III/IV stage
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Fig. 6 Forest plots for the comparisons of survivin expression between patients with LNM and without LNM
Fig. 7 Forest plots for the correlation of survivin expression and tumor size
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Aberrant proliferation of tumor cells may emerge as
cell apoptosis is inhibited, which eventually provided
supports for tumorigenesis, development, invasion
and metastasis [37]. Survivin is one of the most im-
portant inhibitor of IAP family, which is normally
expressed in embryonic and fetal tissues but is almost
absent in terminally differentiated cells [6, 38]. Its
overexpression has been reported in many malignancies
including NSCLC. [39] Several studies have reported
survivin overexpression was involved in the development
of NSCLC [7, 8].
The result of meta-analysis showed a significant differ-
ence in survivin expression between NSCLC patients and
normal controls. To investigate the correlation between
survivin expression and clinicopathologic characteristics,
we performed several meta-analysis in NSCLC patients
classified by clinicopathologic parameters. Our results sug-
gested survivin expression was associated to histological
differentiation, tumor-node-metastasis (TNM) stage and
lymph node metastasis (LNM). Roles of survivin in the
progression of NSCLC have been investigated previously.
Babaei et al. reported survivin is associated with high
grade malignancies. [40] Significant overexpression of sur-
vivin was observed in NSCLC patients at late stage. [41] A
strong heterogeneity was detected among individual stud-
ies. Meta-regression indicated ethnicity was the primary
source of heterogeneity. In the subgroup analysis classified
by ethnicity, the significant associations were still present
in Asians but not in Caucasians. One possible reason was
that only few studies were conducted in Caucasians and
no firm conclusions can be draw from a small sample set.
Further research with large sample size is needed to define
the impact of survivin expression in Caucasians.
Survivin has been shown to localize in mitochondria,
cytoplasm and nucleus. And the functional dynamics of
survivin are dependent on its subcellular localization.
[42] Localization of survivin to the nucleus and cyto-
plasm confers its role in mitosis regulation and apoptosis
inhibition. [43] In nucleus, survivin is involved in the
chromosomal packaging complex and controls mitosis
in many aspects including regulations of the mitotic
spindle checkpoint and mitotic progression. [44] As an
inhibitor in IAP family, survivin can directly inhibit
caspase-3 and caspase-7 activity to prevent apoptosis [5].
In the studies included in our meta-analysis, most stud-
ies reported cytosol survivin expression only. Several
studies defined positive expression as survivin expression
in cytoplasm or nucleus. Only in 2 studies survivin ex-
pression in both cytoplasm and nucleus was considered
as positive expression. We performed subgroup analysis
according to the subcellular localization of survivin and
only found the 2 studies with survivin expression in both
cytoplasm and nucleus gave different results with other
subgroups. Further research is necessary to determine
with precision whether there is a correlation between
subcellular localization of survivin expression and pro-
gression of NSCLC.
There were several limitations in our present meta-
analysis. First, for the insufficiency of data, we did not
analyze whether survivin expression is correlated the
Table 2 Summary of subgroup analysis by ethnicity
Studies Ethnicity (n) Studies (n) Combined RR (95 % CI) P(Z) I2 P(Q)
NSCLC vs. Control All 19 7.16(4.63-11.07) <0.001 58.1 % 0.001
Asians 18 6.60(4.33-10.05) <0.001 55..4 % 0.002
Caucasians 1 101(6.34-1608) 0.001 / /
Squamous cell carcinoma vs. Adenocarcinoma All 22 1.00(0.93, 1.07) 0.983 7.0 % 0.367
Asians 19 0.97(0.90-1.05) 0.44 0 % 0.189
Caucasians 3 1.01(0.78-1.30) 0.959 40.0 % 0.515
Well/Moderately differentiated vs. Poor differentiated All 21 0.80(0.73-0.87) <0.001 45.4 % 0.013
Asians 20 0.78(0.72-0.86) <0.001 33 % 0.077
Caucasians 1 0.96(0.86-1.08) 0.487 / /
TNMI/II stage vs. TNM III/IVstage All 26 0.75(0.67-0.84) <0.001 72.7 % <0.001
Asians 22 0.74(0.65-0.84) <0.001 71.4 % <0.001
Caucasians 4 0.89(0.75-1.07) 0.222 39 % 0.178
Lymph node metastasis vs. Non lymph node metastasis All 25 1.14(1.01-1.29) 0.035 71.5 % <0.001
Asians 22 1.16(1.01-1.34) 0.037 72.7 % <0.001
Caucasians 3 1.03(0.80-1.32) 0.839 64.2 % 0.061
Small Tumor vs. Big Tumor All 11 0.95(0.86-1.05) 0.336 18.1 % 0.272
Asians 9 0.98(0.85-1.13) 0.796 31 % 0.171
Caucasians 2 0.90(0.78-1.04) 0.161 0 % 0.729
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prognosis of NSCLC. Secondly, although our meta-
analysis included 28 studies, only 4 studies were per-
formed in Caucasians. Thus, no firm conclusions can be
draw in Caucasians and the difference between Asians
and Caucasians is uncertain.
Conclusions
In conclusion, although our meta-analysis has some
shortcomings, it still provides evidence that survivin ex-
pression was associated with the clinicopathologic char-
acteristics of NSCLC in Asians, suggesting that survivin
protein can serves as an important biomarker for the
progression of NSCLC. However, further investigations
with more integral data are needed to determine the cor-
relation of survivin expression and the progression of
NSCLC in Caucasians.
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Coefficient SE t P 95 % CI
LL UL
Country 82.25 25.89 3.18 0.037 27.37 137.13
Ethnicity 78.35 27.13 3.08 0.025 26.15 120.65
Language 8.82 18.07 0.49 0.598 −29.49 47.12
Sample Size −0.18 0.37 −0.49 0.234 −26.96 102.39
(Notes: SE = Standard Error; LL = Lower Limit; UL = Upper Limit)
Table 3 Summary of subgroup analysis by localization of survivin expression
Contrasts Subcellular locolization Study (n) Combined RR (95 % CI) P(Z) I2 P(Q)
NSCLC vs. Control All 19 7.16(4.63-11.07) <0.001 58.1 % 0.001
Cytoplasma 9 7.14(4.19-12.16) <0.001 43.8 % 0.076
Cytoplasma or nuclearus 5 3.96(1.93-8.14) <0.001 46.1 % 0.115
Cytoplasma and nuclearus 2 17.41(1.2-252.4) 0.036 70.5 % 0.065
Squamous cell carcinoma vs. Adenocarcinoma All 22 0.99(0.92, 1.07) 0.866 7.0 % 0.367
Cytoplasma 11 0.98(0.88-1.08) 0.641 0 % 0.767
Cytoplasma or nuclearus 6 0.98(0.83-1.15) 0.771 30.8 % 0.204
Cytoplasma and nuclearus 2 1.74(1.12-2.71) 0.013 0 % 0.324
Well/Moderately differentiated vs. Poor differentiated All 21 0.80(0.73-0.87) <0.001 45.4 % 0.013
Cytoplasma 8 0.84(0.75-0.93) 0.001 19.6 % 0.274
Cytoplasma or nuclearus 7 0.68(0.52-0.88) 0.003 68.9 % 0.004
Cytoplasma and nuclearus 2 0.73(0.46-1.16) 0.179 42.7 % 0.186
TNMI/II stage vs. TNM III/IVstage All 26 0.75(0.67-0.84) <0.001 72.7 % <0.001
Cytoplasma 12 0.83(0.69-1.01) 0.059 74.1 % <0.001
Cytoplasma or nuclearus 8 0.73(0.61-0.88) 0.001 74.5 % <0.001
Cytoplasma and nuclearus 2 0.73(0.41-1.29) 0.278 59.7 % 0.115
Lymph node metastasis vs. Non lymph node metastasis All 25 1.14(1.01-1.29) 0.035 71.5 % <0.001
Cytoplasma 10 1.24(1.07-1.44) 0.005 53.1 % 0.024
Cytoplasma or nuclearus 9 1.12(0.89-1.41) 0.352 76.6 % <0.001
Cytoplasma and nuclearus 2 0.96(0.32-2.91) 0.949 83.1 % 0.015
Small Tumor vs. Big Tumor All 11 0.95(0.86-1.05) 0.336 18.1 % 0.272
Cytoplasma 6 0.97(0.79-1.19) 0.738 48.3 % 0.085
Cytoplasma or nuclearus 4 0.92(0.83-1.04) 0.226 0 % 0.565
Cytoplasma and nuclearus 1 1.09(0.71-1.67) 0.691 / /
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